GME Meeting Planner
Fourth Annual Psychopharmacology Update
Join fellow healthcare professionals for this symposium featuring the world's leading experts who will discuss the latest advances in the pharmacotherapy of anxiety disorders, mood disorders, schizophrenia, and more.
Overview
This activity is jointly provided by Postgraduate Institute for Medicine and Global Medical Education.
This symposium featuring the world's leading experts who will discuss the latest advances in the pharmacotherapy of anxiety disorders, mood disorders, schizophrenia, and more.
Discounted Room Block at JW Marriott, Washington, D.C.
GME is pleased to offer a discounted room rate for attendees at this meeting. To make your reservations, please follow the link below or call the hotel directly and mention Global Medical Education. We do expect rooms to sell out quickly, so please book your rooms early!
Web Address: https://aws.passkey.com/gt/215885189?gtid=950e6352267391c7a333d7cc3c3191d2
Phone: 1-800-393-2503 (Reference the Global Medical Education Psychopharmacology group.)
This activity is supported by an independent educational grant from Neurocrine Biosciences, Sage, Shire, and Sunovion.
Target Audience
This activity is intended for physicians, physician assistants, nurse practitioners, psychologists, registered nurses and other healthcare professionals engaged in the care of patients with psychiatric disorders.
Educational Objectives
After completing this activity, the participant should be better able to:
• Implement evidence based pharmacotherapy for mood, anxiety disorders, and schizophrenia.
• Assess the latest advances in the management of postpartum depression.
• Employ the appropriate treatment of substance dependence.
• Evaluate the role of innovative treatments in treatment resistant depression.
• Provide appropriate care and counsel for patients and their families.
• Discuss the management of TD in psychiatric patients.
• Discuss the unmet needs in pharmacotherapy of ADHD across the lifecycle.
• Encourage the use of evidence based treatments for anxiety disorders.
• Discuss the role of ketamine to treat psychiatric disorders including the side effects and concerns.
• Individualize treatment choices, giving consideration to efficacy, safety, long-term data, and unique patient characteristics.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Global Medical Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 13.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 13.0 contact hour(s) (1.30 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number: JA4008162-9999-18-342-L01-P)
Type of Activity: Application
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 13.0 contact hours. Designated for 5.4 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.
Continuing Psychology Education
Postgraduate Institute for Medicine (PIM) is approved by the American Psychological Association to sponsor continuing education for psychologists. PIM maintains responsibility for this program and its content.
This program offers 13.0 continuing education credits for psychologists.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Americans with Disabilities Act (required for live meetings only)
Event staff will be glad to assist you with any special needs (i.e., physical, dietary, etc). Please contact GME Customer Service prior to the live event at [email protected]
Fee Information
There is no fee for this educational activity.
Program Agenda
Tentative Agenda
Day 1 - Saturday, September 8
7:30 - 8:15 AM: Registration and Breakfast
8:15 - 8:30 AM: Opening Remarks by Chair
8:30 - 9:30 AM: “Pharmacotherapy of Bipolar Depressive Spectrum Disorders” - Joseph Goldberg, MD, Mount Sinai
9:30 - 10:30 AM: “Pharmacotherapies for Psychiatric Disorders: What Does The Future Hold” - Roger McIntyre, MD, University of Toronto
10:30 - 11:30 AM: “Pharmacotherapy of Schizophrenia” - Oliver Freudenreich, MD, Harvard
11:30 - 11:45 AM: Break
11:45 AM - 12:45 PM: Hot Topics (Six clinically relevant and topical issues for 8 minutes each)
12:45-2:00 PM: Lunch
2:00 – 3:00 PM: “Pharmacotherapy of Premenstural, Perimenopausal and Postpartum Depression” - Jeff Newport, MD, University of Miami
3:00 – 4:00 PM: “Pharmacotherapy of Antipsychotic Induced Movement Disorders” - Thomas Schwartz, MD, SUNY Upstate
4:00 – 5:00 PM: “Pharmacotherapy of Narcolepsy and Insomnia” - Milton Erman, MD, University of California, San Diego
Day 2 - Sunday, September 9
7:30 – 8:30 AM: Breakfast
8:30 – 9:30 AM: “Pharmacotherapy of Anxiety Disorders” - James Murrough, MD, Mt. Sinai
9:30 – 10:30 AM: “Pharmacotherapy of Binge Eating Disorder” - Carlos Grilo, PhD, Yale
10:30 – 11:30 AM: “Pharmacotherapy of ADHD Across The Life Cycle” - Anthony Rostain, MD, University of Pennsylvania
11:30 -11:45 AM: Break
11:45 AM – 12:45 PM: Hot Topics (Six clinically relevant and topical issues for 8 minutes each)
12:45 – 2:00 PM: Lunch
2:00 – 3:00 PM: “Pharmacotherapy of Opioid and Alcohol Abuse Disorders in Psychiatric Patients” - Ashwin Patkar, MD, Duke
3:00 – 4:00 PM: “Pharmacotherapy of Treatment Resistant Mood Disorders” - Prakash Masand, MD, Duke-NUS
Faculty Members Scheduled to Attend